Common Contracts

AMENDED AND RESTATED STOCKHOLDERS AGREEMENT among LIPIMETIX DEVELOPMENT, INC. and THE STOCKHOLDERS NAMED HEREIN Dated as of August 25, 2016 LIPIMETIX DEVELOPMENT, INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENT

Stockholders Agreement • August 26th, 2016 • Capstone Therapeutics Corp. • Pharmaceutical preparations • Delaware

• Contract Type
  Stockholders Agreement
• Filed
  August 26th, 2016
• Company
  Capstone Therapeutics Corp.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

ThiS AMENDED AND RESTATED Stockholders Agreement (this “Agreement”) is made and entered into as of August 25, 2016 by and among LipimetiX Development, Inc., a Delaware corporation (the “Company”), Capstone Therapeutics Corp., a Delaware corporation (“CAPS”), each of the stockholders listed on the signature page hereto as the LX Stockholders (collectively, the “LX Stockholders”), The UAB Research Foundation (“UABRF”), each of the holders of Series B Preferred Stock listed on Schedule 1 hereto and any subsequent purchasers of the Series B Preferred Stock who become parties to this Agreement pursuant to the terms hereof (collectively, the “Series B Investors”), and any other subsequent stockholders of the Company who become parties to this Agreement pursuant to the terms hereof (each a “Stockholder” and, collectively, the “Stockholders”). CAPS, the LX Stockholders and UABRF are sometimes referred to herein collectively as the “Original Stockholders.”

STOCKHOLDERS AGREEMENT among LIPIMETIX DEVELOPMENT, INC. and THE STOCKHOLDERS NAMED HEREIN Dated as of June 23, 2015

Stockholders Agreement • June 26th, 2015 • Capstone Therapeutics Corp. • Pharmaceutical preparations • Delaware

• Contract Type
  Stockholders Agreement
• Filed
  June 26th, 2015
• Company
  Capstone Therapeutics Corp.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of June 23, 2015 by and among LipimetiX Development, Inc., a Delaware corporation (the “Company”), Capstone Therapeutics Corp., a Delaware corporation (“CAPS”), each of the stockholders listed on the signature page hereto as the LX Stockholders (collectively, the “LX Stockholders”), and The UAB Research Foundation (“UABRF”), and any subsequent stockholders of the Company who become parties to this Agreement pursuant to the terms hereof (each a “Stockholder” and, collectively, the “Stockholders”).